← Eichor
Study identifier: NCT06482268 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)

Condition: PD - Parkinson's Disease  ·  Sponsor: University of California, San Diego

PhasePhase 1
Planned participants7
Who can joinAll sexes, 40 Years to 75 Years
Healthy volunteersNo

About this study

To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease

This description comes directly from the study's public registry record.

Talk to the study team

Christian Fulinara  ·  (858) 2494020  ·  chfulinara@health.ucsd.edu

Donna Brusch  ·  (760) 505-6649  ·  dbrusch@health.ucsd.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of California, San DiegoLa Jolla, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06482268